

February 18, 2014
Nissan Chemical Industries, Ltd.

To whom it may concern:

Sales of Fluralaner, active substance of Veterinary Medical Product

As of February 17, 2014, MSD Animal Health, known as Merck Animal Health in the United States and Canada announced that veterinary medical product BRAVECTO™ chewable tablets for dogs have been granted marketing authorization in EU (European Union), which contain a new ectoparasiticide for companion animals, fluralaner invented by Nissan Chemical. BRAVECTO will be launched by MSD Animal Health in Germany, Spain, Italy, France, the Netherlands and the United Kingdom in April 2014.

BRAVECTO has been developed by MSD Animal Health as a veterinary medical product; it provides unique immediate and persistent tick and flea killing activity for dogs for 12 weeks (8 weeks for *Rhipicephalus sanguineus* ticks), longer than currently available once-monthly commercialized products.

The active substance of BRAVECTO, fluralaner belonging to the isoxazoline group possesses a new mode of action different from currently available once-monthly products, and Nissan Chemical supplies it to MSD Animal Health.

MSD Animal Health plans to introduce BRAVECTO in additional European countries in the coming months, and endeavors to obtain marketing authorization in the other countries including Japan.

About MSD Animal Health

MSD Animal Health (Head quarter in New Jersey, the United States), the global animal health business unit of Merck & Co., Inc., is present in more than 50 countries, while its products are available in some 150 markets. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.

BRAVECTO™ is a trademark of MSD Animal Health, Summit N.J., USA